1 episode causing eye issue; making driving car very difficult; confined to bed; nausea; vomiting; leading to DKA; Severe dizziness; loss of imbalance/imbalance; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 64 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date Apr2021 (Lot number: EW0151) at the age of 64 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Diabetes type 1" (unspecified if ongoing); "High blood pressure" (unspecified if ongoing); "Low thyroidyroprid" (unspecified if ongoing). Concomitant medication(s) included: DULOXETINE; LOSARTIN; EUTHYROX. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: ER8730, Location of injection: Arm Left), administration date: Mar2021, when the patient was 64 years old, for Covid-19 Immunization. The following information was reported: DIABETIC KETOACIDOSIS (hospitalization, medically significant, life threatening) with onset Oct2021, outcome "unknown", described as "leading to DKA"; DIZZINESS (hospitalization, life threatening) with onset Oct2021, outcome "unknown", described as "Severe dizziness"; EYE DISORDER (hospitalization, life threatening) with onset Feb2022, outcome "recovering", described as "1 episode causing eye issue"; IMPAIRED DRIVING ABILITY (hospitalization, life threatening) with onset Feb2022, outcome "recovering", described as "making driving car very difficult"; BALANCE DISORDER (hospitalization, life threatening) with onset Sep2021, outcome "unknown", described as "loss of imbalance/imbalance"; BEDRIDDEN (hospitalization, life threatening) with onset Nov2021, outcome "unknown", described as "confined to bed"; NAUSEA (hospitalization, life threatening) with onset Oct2021, outcome "unknown", described as "nausea"; VOMITING (hospitalization, life threatening) with onset Oct2021, outcome "unknown", described as "vomiting". The patient was hospitalized for diabetic ketoacidosis, dizziness, eye disorder, impaired driving ability, balance disorder, bedridden, nausea, vomiting (hospitalization duration: 2 day(s)). The events "leading to dka", "severe dizziness", "1 episode causing eye issue", "making driving car very difficult", "loss of imbalance/imbalance", "confined to bed", "nausea" and "vomiting" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (Oct2021) negative. Therapeutic measures were taken as a result of diabetic ketoacidosis, dizziness, eye disorder, impaired driving ability, balance disorder, bedridden, nausea, vomiting with 8 bags IV fluids. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient had not diagnosed with COVID-19 prior to vaccination and was tested for COVID-19. Patient did not have known allergies. It was reported that, in Sep2021 patient experienced feelings and loss of imbalance. In Oct2021 severe dizziness with nausea and vomiting, leading to DKA and hospitalization, in Nov2021 3 episodes similar to Oct, less severe, confined to bed, in Dec2021 2 episodes similar to Nov2021, Jan2022 1 episode similar to Dec2021, Feb2022 1 episode causing eye issue and imbalance, making driving car very difficult; improvement after a few hours.